A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.

ABSTRACT:

Background and purpose

rhuMAb Beta7 is a humanized anti-human β7 monoclonal antibody currently in phase I in inflammatory bowel disease. rhuMAb Beta7 binds the β7 subunit of the integrins α4β7 and αEβ7, blocking interaction with their ligands. These integrins play key roles in immune cell homing to and retention in mucosal sites, and are associated with chronic inflammatory diseases of the gastrointestinal tract. The goal of this study was to evaluate the mucosal specificity of rhuMAb Beta7.

Experimental approach

We assessed the effect of murine anti-Beta7 on lymphocyte homing in mouse models of autoimmune disease. We also compared the effect of rhuMAb Beta7 on circulating mucosal-homing versus peripheral-homing T cells in naïve non-human primates.

Key results

In cyno

SUBMITTER: Stefanich EG 

PROVIDER: S-EPMC3081127 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature